Arnold Hanish Sells 10,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 10,000 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at $94,750. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Omeros Stock Down 3.5%

Shares of OMER stock traded down $0.67 on Friday, reaching $18.58. The company had a trading volume of 1,143,548 shares, compared to its average volume of 1,711,871. The stock has a market capitalization of $1.35 billion, a PE ratio of 14.52 and a beta of 2.54. The business’s 50-day moving average is $12.48 and its 200 day moving average is $11.98. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. On average, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OMER. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of OMER. State of Wyoming bought a new position in Omeros during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Omeros in the fourth quarter valued at $33,000. Assetmark Inc. bought a new stake in Omeros in the first quarter valued at $38,000. Arax Advisory Partners raised its holdings in shares of Omeros by 56.4% during the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,894 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in shares of Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.